1. Home
  2. ORIO vs NRSN Comparison

ORIO vs NRSN Comparison

Compare ORIO & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ORIO

Orion Digital Corp. Common Shares

N/A

Current Price

$0.98

Market Cap

22.3M

Sector

N/A

ML Signal

N/A

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.83

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORIO
NRSN
Founded
N/A
2017
Country
Canada
Israel
Employees
188
16
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.3M
26.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ORIO
NRSN
Price
$0.98
$0.83
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
39.4K
143.3K
Earning Date
03-12-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$74.52
N/A
Revenue Next Year
$5.07
$583.67
P/E Ratio
$4.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.63
52 Week High
$1.40
$2.60

Technical Indicators

Market Signals
Indicator
ORIO
NRSN
Relative Strength Index (RSI) 37.85 51.83
Support Level N/A $0.67
Resistance Level $1.11 $0.86
Average True Range (ATR) 0.05 0.06
MACD -0.01 -0.00
Stochastic Oscillator 8.33 35.02

Price Performance

Historical Comparison
ORIO
NRSN

About ORIO Orion Digital Corp. Common Shares

Orion Digital Corp is a financial technology company operating digital platforms across wealth and payments, supported by a consumer lending business in Canada. The Company's Wealth platform, Intelligent Investing, provides long-term investment solutions to the Canadian market. It also operates a consumer lending business in Canada. Its Payments business is conducted through its wholly owned subsidiary, which provides issuer processing, program management, and regulated payment orchestration services across Europe. The Company operates in Canada and Europe, with Canada generating the majority of its revenue.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: